71 related articles for article (PubMed ID: 22938412)
1. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma.
Zhang ZY; Dong JH; Chen YW; Wang XQ; Li CH; Wang J; Wang GQ; Li HL; Wang XD
Asian Pac J Cancer Prev; 2012; 13(6):2503-9. PubMed ID: 22938412
[TBL] [Abstract][Full Text] [Related]
2. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.
Bacigalupo ML; Manzi M; Rabinovich GA; Troncoso MF
World J Gastroenterol; 2013 Dec; 19(47):8831-49. PubMed ID: 24379606
[TBL] [Abstract][Full Text] [Related]
3. Coagulation factor VII and malignant progression of hepatocellular carcinoma.
Chen KD; Huang KT; Tsai MC; Wu CH; Kuo IY; Chen LY; Hu TH; Chen CL; Lin CC
Cell Death Dis; 2016 Feb; 7(2):e2110. PubMed ID: 26913602
[No Abstract] [Full Text] [Related]
4. Galectin-9 in cancer therapy.
Fujihara S; Mori H; Kobara H; Rafiq K; Niki T; Hirashima M; Masaki T
Recent Pat Endocr Metab Immune Drug Discov; 2013 May; 7(2):130-7. PubMed ID: 23514536
[TBL] [Abstract][Full Text] [Related]
5. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer.
Jiang J; Jin MS; Kong F; Cao D; Ma HX; Jia Z; Wang YP; Suo J; Cao X
PLoS One; 2013; 8(12):e81799. PubMed ID: 24339967
[TBL] [Abstract][Full Text] [Related]
6. Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers.
Chan SW; Kallarakkal TG; Abraham MT
Asian Pac J Cancer Prev; 2014; 15(5):2145-52. PubMed ID: 24716948
[TBL] [Abstract][Full Text] [Related]
7. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion.
Oomizu S; Arikawa T; Niki T; Kadowaki T; Ueno M; Nishi N; Yamauchi A; Hattori T; Masaki T; Hirashima M
PLoS One; 2012; 7(11):e48574. PubMed ID: 23144904
[TBL] [Abstract][Full Text] [Related]
8. Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis.
Heusschen R; Schulkens IA; van Beijnum J; Griffioen AW; Thijssen VL
Biochim Biophys Acta; 2014 Feb; 1842(2):284-92. PubMed ID: 24333696
[TBL] [Abstract][Full Text] [Related]
9. The Dual Role of the NFATc2/galectin-9 Axis in Modulating Tumor-Initiating Cell Phenotypes and Immune Suppression in Lung Adenocarcinoma.
Xiao ZJ; Wang SQ; Chen JJ; Li Y; Jiang Y; Tin VP; Liu J; Hu H; Wong MP; Pan Y; Yam JWP
Adv Sci (Weinh); 2024 May; 11(20):e2306059. PubMed ID: 38528665
[TBL] [Abstract][Full Text] [Related]
10. Myeloid cells as potential targets for immunotherapy in pediatric gliomas.
Frederico SC; Sharma N; Darling C; Taori S; Dubinsky AC; Zhang X; Raphael I; Kohanbash G
Front Pediatr; 2024; 12():1346493. PubMed ID: 38523840
[TBL] [Abstract][Full Text] [Related]
11. Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target.
Zhang M; Liu C; Li Y; Li H; Zhang W; Liu J; Wang L; Sun C
Front Cell Dev Biol; 2023; 11():1332205. PubMed ID: 38264357
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers in Cancer Detection, Diagnosis, and Prognosis.
Das S; Dey MK; Devireddy R; Gartia MR
Sensors (Basel); 2023 Dec; 24(1):. PubMed ID: 38202898
[TBL] [Abstract][Full Text] [Related]
13. Galectin-9 Expression is Correlated to Cervical Squamous Cell Carcinoma Progression and Overall Survival.
Mendieta-Carmona V; Delgado-López G; Reyes-Leyva J; Gutiérrez-Quiroz CT; Vazquez-Zamora VJ; Picazo-Mendoza DA; Montiel-Jarquín AJ; Martinez-Morales LP; Vallejo-Ruiz V
Onco Targets Ther; 2023; 16():891-904. PubMed ID: 37927328
[TBL] [Abstract][Full Text] [Related]
14. A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9).
Lv Y; Ma X; Ma Y; Du Y; Feng J
Genes Dis; 2023 Nov; 10(6):2366-2382. PubMed ID: 37554219
[TBL] [Abstract][Full Text] [Related]
15. Galectin-9 in Gastroenterological Cancer.
Morishita A; Oura K; Tadokoro T; Shi T; Fujita K; Tani J; Atsukawa M; Masaki T
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047155
[TBL] [Abstract][Full Text] [Related]
16. Galectin-9 expression clinically associated with mature dendritic cells infiltration and T cell immune response in colorectal cancer.
Wang Y; Zheng R; Zhang Y; Guo Y; Hui Z; Wang P; Sun Y
BMC Cancer; 2022 Dec; 22(1):1319. PubMed ID: 36527024
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the expression levels of T-cell immunoglobulin mucin-3 and its ligand galectin-9 for relapse-free survival in triple-negative breast cancer.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
Oncol Lett; 2022 Jun; 23(6):197. PubMed ID: 35572493
[TBL] [Abstract][Full Text] [Related]
18. Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma.
Jiao J; Jiao D; Yang F; Zhang J; Li Y; Han D; Zhang K; Wang Y; Zhang R; Yang AG; Wang A; Wen W; Qin W
Aging (Albany NY); 2022 Feb; 14(4):1879-1890. PubMed ID: 35202002
[TBL] [Abstract][Full Text] [Related]
19. Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity.
Ustyanovska Avtenyuk N; Choukrani G; Ammatuna E; Niki T; Cendrowicz E; Lourens HJ; Huls G; Wiersma VR; Bremer E
Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052746
[TBL] [Abstract][Full Text] [Related]
20. Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells.
Zhao S; Wang C; Lu P; Lou Y; Liu H; Wang T; Yang S; Bao Z; Han L; Liang X; Ma C; Gao L
J Immunother Cancer; 2021 Nov; 9(12):. PubMed ID: 34853180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
